Frankfurt Researchers Recruit for Bupropion Post-COVID Fatigue Trial
Researchers at the University Hospital Frankfurt are recruiting participants for a new clinical trial investigating whether the antidepressant bupropion can alleviate persistent fatigue in patients suffering from Post-COVID syndrome.
The study, which launched in the summer of 2026, aims to enroll 250 patients to evaluate if the drug’s mechanism of action can address the debilitating exhaustion common in long-term COVID-19 cases, as reported by FAZ, according to PressNews.
Key Clinical Takeaways:
- The RAPID_ELAPSE study is a randomized, double-blind, placebo-controlled trial investigating bupropion as a potential treatment for post-COVID fatigue.
- Bupropion acts as an aminoketone antidepressant that increases the availability of norepinephrine and dopamine, neurotransmitters involved in regulating alertness and attention.
Bupropion is a clinically established medication currently approved for treating depression and supporting smoking cessation. According to PressNews, the drug functions by increasing the synaptic availability of norepinephrine and dopamine. These neurotransmitters are critical for cognitive function, wakefulness, and physical stamina, leading researchers to hypothesize that the drug may mitigate the profound exhaustion and reduced physical resilience characteristic of post-COVID syndrome.
The study, titled RAPID_ELAPSE, seeks to address the current lack of approved pharmacological therapies for the condition. “Beim Post-COVID-Syndrom wissen wir noch zu wenig darüber, welche Krankheitsmechanismen die anhaltenden Beschwerden verursachen,” said Prof. Dr. Maria Vehreschild, head of the infectious diseases department at University Hospital Frankfurt and sponsor representative for the project.
She added that the study aims to identify specific patient characteristics that could guide more targeted treatments in the future.
The trial is structured as an adaptive, randomized, double-blind, and placebo-controlled investigation. Beyond tracking the severity of fatigue, the research team is collecting data on respiratory symptoms, cognitive impairment, and neuropsychiatric health. To maintain patient safety, physical performance testing is conducted without exceeding the individual participant’s established exertion limits, FAZ reported.
The researchers are also collecting biological samples from the 250 prospective participants. This methodology is intended to uncover potential biomarkers or underlying commonalities across different patient cohorts. “Bislang fehlen jedoch kontrollierte Studien, die die Wirksamkeit bei Post-COVID belegen,” explained Dr. Sinem Koc-Günel, a specialist in internal medicine and lead researcher at the University Hospital Frankfurt, to PressNews.
“RAPID_ELAPSE soll zeigen, ob Bupropion im Vergleich zu einem Placebo die Fatigue verringert und die körperliche Funktionsfähigkeit der Patientinnen und Patienten verbessert.”, according to FAZ
The condition known as Post-COVID syndrome is defined by symptoms that persist for at least two months, beginning no earlier than three months after the initial infection, and which cannot be explained by an alternative diagnosis.
Patients in the Frankfurt region interested in participating in the trial are being screened to determine their eligibility. Prospective volunteers may contact the research team via the email address provided by the university clinic to undergo an individual assessment. This trial follows previous investigations into the efficacy of the drug for cancer-associated fatigue, where the medication was also evaluated for its impact on significant exhaustion levels, FAZ reported.
As this study progresses, patients experiencing persistent, debilitating fatigue or neurological symptoms should continue to coordinate closely with their primary care physicians or specialists in infectious disease and internal medicine. Managing such complex, multi-systemic symptoms often requires a multidisciplinary approach to ensure that individual health markers are monitored safely while new clinical options are explored.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.